Notice of Change to RFA-AG-21-003 New/Unconventional Animal Models of Alzheimer’s Disease (R24 Clinical Trial Not Allowed)
Notice Number:
NOT-AG-20-047

Key Dates

Release Date:

August 18, 2020

Related Announcements

RFA-AG-21-003 - New/Unconventional Animal Models of Alzheimer’s Disease (R24 Clinical Trial Not Allowed)

Issued by

National Institute on Aging (NIA)

Purpose

This Notice informs potential applicants of the following changes to RFA-AG-21-003 New/Unconventional Animal Models of Alzheimer’s Disease (R24 Clinical Trial Not Allowed):

Current language:

Part 1. Overview Information

Funding Opportunity Purpose

This funding opportunity announcement (FOA) invites research to develop, characterize, and validate new, unconventional, or innovative non-rodent mammalian models of late-onset (sporadic) Alzheimer's Disease (AD). These new models are expected to recapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive hallmarks and aspects of late-onset AD.Research supported under this FOA is expected to provide new investigative tools to identify the gaps in current knowledge related to molecular mechanisms of late-onset AD and identify potential therapeutic targets.

Part 2. Section III. Eligibility Information

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Modified to read:

Part 1. Overview Information

Funding Opportunity Purpose

This funding opportunity announcement (FOA) invites research to develop, characterize, and validate new, unconventional, or innovative mammalian models (excluding mice) of late-onset (sporadic) Alzheimer's Disease (AD). These new models are expected to recapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive hallmarks and aspects of late-onset AD.Research supported under this FOA is expected to provide new investigative tools to identify the gaps in current knowledge related to molecular mechanisms of late-onset AD and identify potential therapeutic targets.

Part 2. Section III. Eligibility Information

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Manuel Moro, DVM, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-480-1796
Email: [email protected]


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices